&omega;‑3 fatty acids in atherosclerotic cardiovascular disease (Review)

Xie,Xingxing; Liu,Xue; Li,Rong; Fan,Ling; Huang,Fujing

doi:10.3892/br.2024.1782

ω‑3 fatty acids in atherosclerotic cardiovascular disease (Review)

Authors:
- Xingxing Xie
- Xue Liu
- Rong Li
- Ling Fan
- Fujing Huang
View Affiliations

Affiliations: Department of Pharmacy, Yaan People's Hospital, Yaan, Sichuan 625000, P.R. China, Clinical Trial Center for Drugs and Medical Devices, Yaan People's Hospital, Yaan, Sichuan 625000, P.R. China
Published online on: April 19, 2024 https://doi.org/10.3892/br.2024.1782
Article Number: 94
Copyright: © Xie et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Atherosclerotic cardiovascular disease (ASCVD) is one of the most common chronic diseases in the world. Epidemiological evidence and clinical trials have shown that ω‑3 fatty acids have a variety of promoting effects in reducing the risk of ASCVD, but different conclusions of large randomized controlled trials make their clinical use in the prevention and treatment of ASCVD controversial. The present review focuses on the pharmacological mechanism, clinical trials and evidence value of clinical applications of ω‑3 fatty acids in order to provide theoretical and practical evidence for the clinical application strategy, and follow‑up research and development of ω‑3 fatty acids as anti‑ASCVD drugs.

View Figures

View References

1	Li C, Liu X, Adhikari BK, Chen L, Liu W, Wang Y and Zhang H: The role of epicardial adipose tissue dysfunction in cardiovascular diseases: An overview of pathophysiology, evaluation, and management. Front Endocrinol (Lausanne). 14(1167952)2023.PubMed/NCBI View Article : Google Scholar
2	Libby P: The changing landscape of atherosclerosis. Nature. 592:524–533. 2021.PubMed/NCBI View Article : Google Scholar
3	Ganda OP, Bhatt DL, Mason RP, Miller M and Boden WE: Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol. 72:330–343. 2018.PubMed/NCBI View Article : Google Scholar
4	Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration. Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, Ouwehand W, Watkins H, Samani NJ, et al: Triglyceride-mediated pathways and coronary disease: Collaborative analysis of 101 studies. Lancet. 375:1634–1639. 2010.PubMed/NCBI View Article : Google Scholar
5	Karlson BW, Palmer MK, Nicholls SJ, Lundman P and Barter PJ: A VOYAGER meta-analysis of the impact of statin therapy on low-density lipoprotein cholesterol and triglyceride levels in patients with hypertriglyceridemia. Am J Cardiol. 117:1444–1448. 2016.PubMed/NCBI View Article : Google Scholar
6	Dong SJ, Bian JL, Chen HS and Zhang RS: A systematic review of omega-3 fatty acids combined with statins for treatment of dyslipidemia. J Clin Pharmacotherapy. 20:21–28. 2019.
7	Mason RP, Sherratt SCR and Eckel RH: Rationale for different formulations of omega-3 fatty acids leading to differences in residual cardiovascular risk reduction. Metabolism. 130(155161)2022.PubMed/NCBI View Article : Google Scholar
8	Mason RP and Eckel RH: Mechanistic insights from REDUCE-IT STRENGTHen the case against triglyceride lowering as a strategy for cardiovascular disease risk reduction. Am J Med. 134:1085–1090. 2021.PubMed/NCBI View Article : Google Scholar
9	Tadic M, Sala C, Grassi G, Mancia G, Taddei S, Rottbauer W and Cuspidi C: Omega-3 fatty acids and coronary artery disease: More questions than answers. J Clin Med. 10(2495)2021.PubMed/NCBI View Article : Google Scholar
10	Saini RK and Keum YS: Omega-3 and omega-6 polyunsaturated fatty acids: Dietary sources, metabolism, and significance-a review. Life Sci. 203:255–267. 2018.PubMed/NCBI View Article : Google Scholar
11	Sheikh O, Vande Hei AG, Battisha A, Hammad T, Pham S and Chilton R: Cardiovascular, electrophysiologic, and hematologic effects of omega-3 fatty acids beyond reducing hypertriglyceridemia: As it pertains to the recently published REDUCE-IT trial. Cardiovasc Diabetol. 18(84)2019.PubMed/NCBI View Article : Google Scholar
12	Baker EJ, Miles EA, Burdge GC, Yaqoob P and Calder PC: Metabolism and functional effects of plant-derived omega-3 fatty acids in humans. Prog Lipid Res. 64:30–56. 2016.PubMed/NCBI View Article : Google Scholar
13	Innes JK and Calder PC: Marine omega-3 (N-3) fatty acids for cardiovascular health: An update for 2020. Int J Mol Sci. 21(1362)2020.PubMed/NCBI View Article : Google Scholar
14	Calder PC: Very long-chain n-3 fatty acids and human health: Fact, fiction and the future. Proc Nutr Soc. 77:52–72. 2018.PubMed/NCBI View Article : Google Scholar
15	Dyall SC: Long-chain omega-3 fatty acids and the brain: A review of the independent and shared effects of EPA, DPA and DHA. Front Aging Neurosci. 7(52)2015.PubMed/NCBI View Article : Google Scholar
16	Mason RP, Sherratt SCR and Eckel RH: Omega-3-fatty acids: Do they prevent cardiovascular disease? Best Pract Res Clin Endocrinol Metab. 37(101681)2023.PubMed/NCBI View Article : Google Scholar
17	Nordestgaard BG: Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: New insights from epidemiology, genetics, and biology. Circ Res. 118:547–563. 2016.PubMed/NCBI View Article : Google Scholar
18	Ginsberg HN, Packard CJ, Chapman MJ, Borén J, Aguilar-Salinas CA, Averna M, Ference BA, Gaudet D, Hegele RA, Kersten S, et al: Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European atherosclerosis society. Eur Heart J. 42:4791–4806. 2021.PubMed/NCBI View Article : Google Scholar
19	Dubois V, Eeckhoute J, Lefebvre P and Staels B: Distinct but complementary contributions of PPAR isotypes to energy homeostasis. J Clin Invest. 127:1202–1214. 2017.PubMed/NCBI View Article : Google Scholar
20	Derosa G, Sahebkar A and Maffioli P: The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice. J Cell Physiol. 233:153–161. 2018.PubMed/NCBI View Article : Google Scholar
21	Jump DB: N-3 polyunsaturated fatty acid regulation of hepatic gene transcription. Curr Opin Lipidol. 19:242–247. 2008.PubMed/NCBI View Article : Google Scholar
22	Mason RP, Jacob RF, Shrivastava S, Sherratt SCR and Chattopadhyay A: Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes. Biochim Biophys Acta. 1858:3131–3140. 2016.PubMed/NCBI View Article : Google Scholar
23	Sherratt SCR, Libby P, Bhatt DL and Mason RP: A biological rationale for the disparate effects of omega-3 fatty acids on cardiovascular disease outcomes. Prostaglandins Leukot Essent Fatty Acids. 182(102450)2022.PubMed/NCBI View Article : Google Scholar
24	Gutiérrez S, Svahn SL and Johansson ME: Effects of omega-3 fatty acids on immune cells. Int J Mol Sci. 20(5028)2019.PubMed/NCBI View Article : Google Scholar
25	Lu LW, Quek SY, Lu SP and Chen JH: Potential benefits of omega-3 polyunsaturated fatty acids (N3PUFAs) on cardiovascular health associated with COVID-19: An update for 2023. Metabolites. 13(630)2023.PubMed/NCBI View Article : Google Scholar
26	Oner F, Alvarez C, Yaghmoor W, Stephens D, Hasturk H, Firatli E and Kantarci A: Resolvin E1 regulates Th17 function and T cell activation. Front Immunol. 12(637983)2021.PubMed/NCBI View Article : Google Scholar
27	Meydani SN, Endres S, Woods MM, Goldin BR, Soo C, Morrill-Labrode A, Dinarello CA and Gorbach SL: Oral (n-3) fatty acid supplementation suppresses cytokine production and lymphocyte proliferation: Comparison between young and older women. J Nutr. 121:547–555. 1991.PubMed/NCBI View Article : Google Scholar
28	Williams-Bey Y, Boularan C, Vural A, Huang NN, Hwang IY, Shan-Shi C and Kehrl JH: Omega-3 free fatty acids suppress macrophage inflammasome activation by inhibiting NF-κB activation and enhancing autophagy. PLoS One. 9(e97957)2014.PubMed/NCBI View Article : Google Scholar
29	Sung J, Jeon H, Kim IH, Jeong HS and Lee J: Anti-inflammatory effects of stearidonic acid mediated by suppression of NF-κB and MAP-kinase pathways in macrophages. Lipids. 52:781–787. 2017.PubMed/NCBI View Article : Google Scholar
30	Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, Li P, Lu WJ, Watkins SM and Olefsky JM: GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 142:687–698. 2010.PubMed/NCBI View Article : Google Scholar
31	Reilly NA, Lutgens E, Kuiper J, Heijmans BT and Jukema JW: Effects of fatty acids on T cell function: Role in atherosclerosis. Nat Rev Cardiol. 18:824–837. 2021.PubMed/NCBI View Article : Google Scholar
32	Yubero-Serrano EM, Fernandez-Gandara C, Garcia-Rios A, Rangel-Zuñiga OA, Gutierrez-Mariscal FM, Torres-Peña JD, Marin C, Lopez-Moreno J, Castaño JP, Delgado-Lista J, et al: Mediterranean diet and endothelial function in patients with coronary heart disease: An analysis of the CORDIOPREV randomized controlled trial. PLoS Med. 17(e1003282)2020.PubMed/NCBI View Article : Google Scholar
33	Vanhoutte PM, Shimokawa H, Feletou M and Tang EH: Endothelial dysfunction and vascular disease-a 30th anniversary update. Acta Physiol (Oxf). 219:22–96. 2017.PubMed/NCBI View Article : Google Scholar
34	Mason RP, Dawoud H, Jacob RF, Sherratt SCR and Malinski T: Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin. Biomed Pharmacother. 103:1231–1237. 2018.PubMed/NCBI View Article : Google Scholar
35	Dang TA, Schunkert H and Kessler T: cGMP signaling in cardiovascular diseases: Linking genotype and phenotype. J Cardiovasc Pharmacol. 75:516–525. 2020.PubMed/NCBI View Article : Google Scholar
36	Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood PC and Deadman NM: Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and reinfarction trial (DART). Lancet. 2:757–761. 1989.PubMed/NCBI View Article : Google Scholar
37	No authors listed. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 354:447–455. 1999.PubMed/NCBI
38	Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, et al: Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. Lancet. 369:1090–1098. 2007.PubMed/NCBI View Article : Google Scholar
39	Rauch B, Schiele R, Schneider S, Diller F, Victor N, Gohlke H, Gottwik M, Steinbeck G, Del Castillo U, Sack R, et al: OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation. 122:2152–2159. 2010.PubMed/NCBI View Article : Google Scholar
40	ORIGIN Trial Investigators. Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, et al: N-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 367:309–318. 2012.PubMed/NCBI View Article : Google Scholar
41	Risk and Prevention Study Collaborative Group. Roncaglioni MC, Tombesi M, Avanzini F, Barlera S, Caimi V, Longoni P, Marzona I, Milani V, Silletta MG, et al: N-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med. 368:1800–1808. 2013.PubMed/NCBI View Article : Google Scholar
42	ASCEND Study Collaborative Group. Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, Murphy K, Aung T, Haynes R, et al: Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med. 379:1540–1550. 2018.PubMed/NCBI View Article : Google Scholar
43	Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, Gibson H, Albert CM, Gordon D, Copeland T, et al: Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med. 380:23–32. 2019.PubMed/NCBI View Article : Google Scholar
44	Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, et al: Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 380:11–22. 2019.PubMed/NCBI View Article : Google Scholar
45	Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJP, Koenig W, McGuire DK, et al: Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: The STRENGTH randomized clinical trial. JAMA. 324:2268–2280. 2020.PubMed/NCBI View Article : Google Scholar
46	Kalstad AA, Myhre PL, Laake K, Tveit SH, Schmidt EB, Smith P, Nilsen DWT, Tveit A, Fagerland MW, Solheim S, et al: Effects of n-3 fatty acid supplements in elderly patients after myocardial infarction: A randomized, controlled trial. Circulation. 143:528–539. 2021.PubMed/NCBI View Article : Google Scholar
47	Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, et al: 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J. 41:111–188. 2020.PubMed/NCBI View Article : Google Scholar
48	Chinese Society of Cardiology of Chinese Medical Association, Cardiovascular Disease Prevention and Rehabilitation Committee of Chinese Association of Rehabilitation Medicine, Cardiovascular Disease Committee of Chinese Association of Gerontology and Geriatrics, Thrombosis Prevention and Treatment Committee of Chinese Medical Doctor Association. Chinese Guideline on the primary prevention of cardiovascular diseases. Zhonghua Xin Xue Guan Bing Za Zhi. 48:1000–1038. 2020.PubMed/NCBI View Article : Google Scholar : (In Chinese).
49	Working Group of the Chinese Expert Consensus on Secondary Prevention after Coronary Artery Bypass Surgery, The Task Force for Coronary Artery Disease of Chinese Association of Cardiovascular Surgeons and The Task Force for Coronary Artery Disease of Chinese Society of Thoracic and Cardiovascular Surgery. Chinese expert consensus on secondary prevention after coronary artery bypass surgery (2020). Chin J Thor Cardi Sur. 37:193–201. 2021.(In Chinese).
50	Hypertension Group, Chinese Society of Cardiology, Editorial Board of Chinese Journal of Cardiology. Expert consensus on comprehensive management of blood pressure and lipids in Chinese patients with hypertension. Zhonghua Xin Xue Guan Bing Za Zhi. 49:554–563. 2021.PubMed/NCBI View Article : Google Scholar : (In Chinese).
51	Centre for Capacity Building and Continuing Education, National Health Commission. Expert consensus on diagnosis and treatment of cardiovascular diseases in diabetic patients. Chin J Inter Med. 60:421–437. 2021.(In Chinese).
52	Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, Kamel H, Kernan WN, Kittner SJ, Leira EC, et al: 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline from the American heart association/American stroke association. Stroke. 52:e364–e467. 2021.PubMed/NCBI View Article : Google Scholar
53	Virani SS, Morris PB, Agarwala A, Ballantyne CM, Birtcher KK, Kris-Etherton PM, Ladden-Stirling AB, Miller M, Orringer CE and Stone NJ: 2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: A report of the American college of cardiology solution set oversight committee. J Am Coll Cardiol. 78:960–993. 2021.PubMed/NCBI View Article : Google Scholar
54	American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: Standards of medical care in diabetes-2022. Diabetes Care. 45 (Suppl 1):S144–S174. 2022.PubMed/NCBI View Article : Google Scholar
55	National Committee of Cardiometabolic Medicine Specialists Committee. The role of omega-3 fatty acids in the prevention and treatment of cardiovascular diseases. Chin J Cir. 38:116–130. 2019.(In Chinese).
56	Li JJ, Zhao SP, Zhao D, Lu GP, Peng DQ, Liu J, Chen ZY, Guo YL, Wu NQ, Yan SK, et al: 2023 China Guidelines for Lipid Management. J Geriatr Cardiol. 20:621–663. 2023.PubMed/NCBI View Article : Google Scholar